Betta Pharmaceuticals - Public Comps and Valuation Multiples

Betta Pharmaceuticals Overview

About Betta Pharmaceuticals

Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.

Founded

2003

HQ

Employees

n/a

Website

bettapharma.com

Sectors

Drug Development & Therapeutics
Small Molecules
BioTech
DeepTech

Financials

LTM Revenue $503M

LTM EBITDA $173M

EV

$3.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Betta Pharmaceuticals Financials

As of November 2025, Betta Pharmaceuticals reported last 12-month revenue of $503M and EBITDA of $173M.

In the same period, Betta Pharmaceuticals generated $408M in LTM gross profit and $82.7M in net income.

See Betta Pharmaceuticals valuation multiples based on analyst estimates

Betta Pharmaceuticals P&L

In the most recent fiscal year, Betta Pharmaceuticals reported revenue of $409M and EBITDA of $115M.

Betta Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Betta Pharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$503M	XXX	$409M	XXX	XXX	XXX
Gross Profit	$408M	XXX	$333M	XXX	XXX	XXX
Gross Margin	81%	XXX	81%	XXX	XXX	XXX
EBITDA	$173M	XXX	$115M	XXX	XXX	XXX
EBITDA Margin	34%	XXX	28%	XXX	XXX	XXX
EBIT	$87.5M	XXX	$70.5M	XXX	XXX	XXX
EBIT Margin	17%	XXX	17%	XXX	XXX	XXX
Net Profit	$82.7M	XXX	$56.9M	XXX	XXX	XXX
Net Margin	16%	XXX	14%	XXX	XXX	XXX
Net Debt	XXX	XXX	$167M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Betta Pharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $503M. EBITDA for the last twelve months was $173M. In the most recent fiscal year, Betta Pharmaceuticals achieved $409M in revenue and $115M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$503M	Analyst estimates available to subscribers	$409M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$408M	Analyst estimates available to subscribers	$333M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	81.1% gross margin	Analyst estimates available to subscribers	81.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$173M	Analyst estimates available to subscribers	$115M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	34.4% EBITDA margin	Analyst estimates available to subscribers	28.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$87.5M	Analyst estimates available to subscribers	$70.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	17.4% EBIT margin	Analyst estimates available to subscribers	17.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$82.7M	Analyst estimates available to subscribers	$56.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	16.4% net profit margin	Analyst estimates available to subscribers	13.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$167M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Betta Pharmaceuticals

This financial data table provides comprehensive performance metrics for Betta Pharmaceuticals, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Betta Pharmaceuticals generated $503M in revenue over the last twelve months.
The company achieved $173M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $408M.
Net income over the last twelve months reached $82.7M.

Fiscal Year Performance

In the most recent fiscal year, Betta Pharmaceuticals reported $409M in total revenue.
Fiscal year EBITDA was $115M.
The company maintained a gross profit margin of 81.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was 28.1%.
Net profit margin reached 13.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Betta Pharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Betta Pharmaceuticals Stock Performance

Betta Pharmaceuticals has current market cap of CNY 20.3B (or $2.9B), and EV of CNY 22.2B (or $3.1B).

Market Cap Evolution

Betta Pharmaceuticals Stock Data

As of December 3, 2025, Betta Pharmaceuticals's stock price is CNY 48 (or $7).

See Betta Pharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.1B	$2.9B	XXX	XXX	XXX	XXX	$0.20

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Betta Pharmaceuticals Valuation Multiples

Betta Pharmaceuticals's trades at 7.7x EV/Revenue multiple, and 27.4x EV/EBITDA.

See valuation multiples for Betta Pharmaceuticals and 15K+ public comps

Betta Pharmaceuticals Financial Valuation Multiples

As of December 3, 2025, Betta Pharmaceuticals has market cap of $2.9B and EV of $3.1B.

Equity research analysts estimate Betta Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Betta Pharmaceuticals has a P/E ratio of 34.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.9B	XXX	$2.9B	XXX	XXX	XXX
EV (current)	$3.1B	XXX	$3.1B	XXX	XXX	XXX
EV/Revenue	6.2x	XXX	7.7x	XXX	XXX	XXX
EV/EBITDA	18.1x	XXX	27.4x	XXX	XXX	XXX
EV/EBIT	35.9x	XXX	44.6x	XXX	XXX	XXX
EV/Gross Profit	7.7x	XXX	n/a	XXX	XXX	XXX
P/E	34.7x	XXX	50.5x	XXX	XXX	XXX
EV/FCF	n/a	XXX	265.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Betta Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Betta Pharmaceuticals Margins & Growth Rates

Betta Pharmaceuticals's last 12 month revenue growth is 22%

Betta Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Betta Pharmaceuticals's rule of 40 is 50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Betta Pharmaceuticals's rule of X is 90% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Betta Pharmaceuticals and other 15K+ public comps

Betta Pharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	22%	XXX	23%	XXX	XXX	XXX
EBITDA Margin	34%	XXX	28%	XXX	XXX	XXX
EBITDA Growth	17%	XXX	35%	XXX	XXX	XXX
Rule of 40	50%	XXX	50%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	90%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	27%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	17%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	64%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial